A FGFR1 inhibitor patent review: progress since 2010. (3rd April 2017)

• Record Type: Journal Article
• Authors: Yu, Tao; Yang, Yanyan; Liu, Yan; Zhang, Yinfeng; Xu, Hong; Li, Mengpeng; Ponnusamy, Murugavel; Wang, Kun; Wang, Jian-Xun; Li, Pei-Feng
• Is Part Of: Expert opinion on therapeutic patents. Volume 27:Number 4(2017:Apr.)
• Page Start: 439
• Page End: 454
• Publication Date: 2017-04-03
• Subjects: FGFR1 inhibitors -- cancer -- angiogenesis -- tyrosine kinase -- clinical evaluation -- drug discovery; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2017.1272574
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : FGFR1 is a well known molecular target for anticancer therapy. Many studies have proved that the regulation of FGFR1 activity is a promising therapeutic approach to treat a series of cancers. Therefore, the development of potent inhibitors has consequently become a key focus in the present drug discovery, and it is encouraging that several highly selective FGFR1 inhibitors have been identified from various sources in recent years. Areas covered : This article reviews patents and patent applications related to selective FGFR1 inhibitors published from 2010 to 2016. This summary highlights about 15 patents from different pharmaceutical companies and academic research groups. We used Baidu and NCBI search engines to find relevant patents as a search term. Expert opinion : In the past few years, considerable progress has been made in the identification and development of selective FGFR1 inhibitors in use. At present, at least 10 inhibitors of FGFR1 are in clinical trials, and several agents have shown encouraging results under experimental conditions. Given the fact that FGFR1 plays a crucial role in the regulation of cancer and other diseases, we hope that it will gain further attraction from pharmaceutical companies and encourage development of more novel, safe and efficient FGFR1 inhibitors in the future.